Equities

Kintara Therapeutics Inc

Kintara Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.286
  • Today's Change0.002 / 0.53%
  • Shares traded2.18m
  • 1 Year change-93.84%
  • Beta0.9330
Data delayed at least 15 minutes, as of Jul 16 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at Kintara Therapeutics Inc fell by 10.25m. Cash Flow from Financing totalled 1.85m or -- of revenues. In addition the company used 11.87m for operations while cash used for investing totalled 232.00k.
Cash flow per share-0.7233
Price/Cash flow per share--
Book value per share0.1071
Tangible book value per share0.1071
More ▼

Balance sheet in USDView more

Kintara Therapeutics Inc uses little or no debt in its capital structure.
Current ratio5.04
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.